Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Intra-Cellular Ther
(NQ:
ITCI
)
51.49
-1.00 (-1.91%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 3, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Intra-Cellular Ther
< Previous
1
2
3
4
Next >
What 10 Analyst Ratings Have To Say About Intra-Cellular Therapies
August 22, 2023
Via
Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
August 03, 2023
Via
Benzinga
Intra-Cellular Therapies Better Positioned For Success: Analyst Anticipates Positive Phase 3 Depression Trial Data
July 06, 2023
Needham increased the price target for Intra-Cellular Therapies Inc (NASDAQ: ITCI) from $70 to $73, with a Buy rating, noting high expectations regarding major depressive disorder (MDD) readouts are...
Via
Benzinga
Needham Maintains Buy Rating for Intra-Cellular Therapies: Here's What You Need To Know
July 06, 2023
Via
Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
June 22, 2023
Via
Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
June 05, 2023
Via
Benzinga
Recap: Intra-Cellular Therapies Q1 Earnings
May 04, 2023
Via
Benzinga
A Preview Of Intra-Cellular Therapies's Earnings
May 03, 2023
Via
Benzinga
Analyst Ratings for Intra-Cellular Therapies
March 29, 2023
Via
Benzinga
Intra-Cellular Stock Surges As Antipsychotic Shows Benefit In Depression Patients With Mixed Features
March 28, 2023
Via
Benzinga
Analyst Ratings for Intra-Cellular Therapies
March 02, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023
April 20, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
April 07, 2023
Via
Benzinga
Airbnb To Rally Around 59%? Here Are 10 Other Analyst Forecasts For Wednesday
March 29, 2023
Keybanc raised the price target for Intuit Inc. (NASDAQ: INTU) from $450 to $475. Keybanc analyst Josh Beck maintained an Overweight rating. Intuit shares fell 1.8% to close at $419.33 on Tuesday.
Via
Benzinga
Earnings Scheduled For March 1, 2023
March 01, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Via
Benzinga
Earnings Outlook For Intra-Cellular Therapies
February 28, 2023
Via
Benzinga
Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 28, 2023
Gainers
Via
Benzinga
Why Intra-Cellular Therapies Climbed Tuesday
March 28, 2023
The company's depression drug, Caplyta (lumateperone), did well in a phase 3 trial against two types of depression.
Via
The Motley Fool
Intra-Cellular's Big Depression Drug Market Just Got Bigger — And Shares Catapulted
March 28, 2023
The company believes it may have the answer for patients with "mixed features."
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 28, 2023
Via
Benzinga
Looking Into Intra-Cellular Therapies's Return On Capital Employed
November 23, 2022
Via
Benzinga
Where Intra-Cellular Therapies Stands With Analysts
August 11, 2022
Within the last quarter, Intra-Cellular Therapies (NASDAQ:ITCI) has observed the following analyst ratings:
Via
Benzinga
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
March 15, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for...
Via
FinancialNewsMedia
Exposures
COVID-19
Recap: Intra-Cellular Therapies Q3 Earnings
November 03, 2022
Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Intra-Cellular Therapies's Earnings: A Preview
November 02, 2022
Intra-Cellular Therapies (NASDAQ:ITCI) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Looking Into Intra-Cellular Therapies's Return On Capital Employed
September 02, 2022
Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $55.58 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 20.08%, resulting in a loss of $86.60...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022
August 22, 2022
Upgrades
Via
Benzinga
Illumina, Poshmark, Olo And Some Other Big Losers From Friday
August 15, 2022
U.S. stocks closed higher on Friday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Intra-Cellular Therapies: Q2 Earnings Insights
August 09, 2022
Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.